![Ian Thomas](https://profiles-cardiff.imgix.net/attachments/3665?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Overview
I am a Research Fellow within the Blood Cancer group, at the UKCRC Registered Centre for Trials Research at Cardiff University.
I have worked on international clinical trials, predominantly in acute myeloid leukaemia, since 2007, having worked in industry and contract research organisations for the previous 5 years.
I have started to develop a broader research portfolio in areas of patient-reported outcomes, inclusivity in clinical trials and in other haematological research areas (both within and outwith cancer). My specific expertise is in delivering platform trials, where a number of different research questions can be investigated in as broad a patient population as possible.
Through the international clinical trials portfolio, I collaborate widely across the UK, Europe and the US and work with a number of different funders including CRUK, BCUK, NIHR and industry.
Publication
2024
- Versluis, J. et al. 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42(34), pp. 4084-4094. (10.1200/JCO.23.02631)
- Russell, N. H. et al. 2024. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology (10.1200/JCO.24.00259)
- Voso, M. T. et al. 2024. Acute promyelocytic leukemia: Long-term outcomes from the HARMONY project. Blood (10.1182/blood.2024026186)
- Rodríguez-Arbolí, E. et al. 2024. Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML) [Letter to the Editor]. Leukemia 38(10) (10.1038/s41375-024-02378-5)
- Othman, J. et al. 2024. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood 144(7), pp. 714-728. (10.1182/blood.2024024310)
- Othman, J. et al. 2024. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143(19), pp. 1931-1936. (10.1182/blood.2023023096)
- Copland, M. et al. 2024. A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 204(3), pp. 871-876. (10.1111/bjh.19220)
2023
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
- Mussai, F. et al. 2023. A randomised evaluation of low‐dose Ara‐ C plus pegylated recombinant arginase BCT ‐100 versus low dose Ara‐ C in older unfit patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 200(5), pp. 573-578. (10.1111/bjh.18560)
2022
- Loo, S. et al. 2022. Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome [Letter]. Blood 140(22), pp. 2407-2411. (10.1182/blood.2022016567)
- Döhner, K. et al. 2022. Analysis of patient-level data from 3 cooperative group trials confirms a survival advantage for NPM1m patients achieving MRD-negative CR after intensive induction. Blood 140(S1), pp. 6293-6294. (10.1182/blood-2022-159212)
- Freeman, S. D. et al. 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140(S1), pp. 532-533. (10.1182/blood-2022-162245)
- Love, S. B. et al. 2022. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials 23, article number: 757. (10.1186/s13063-022-06680-4)
- Russell, N. H. et al. 2022. A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British Journal of Haematology 198(3), pp. 528-534. (10.1111/bjh.18195)
- Tazi, Y. et al. 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13(1), article number: 4622. (10.1038/s41467-022-32103-8)
- Russell, N. H. et al. 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107(7), pp. 1518-1527. (10.3324/haematol.2021.279010)
- Coats, T. et al. 2022. A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia. British Journal of Haematology 196(6), pp. 1337-1343. (10.1111/bjh.18013)
- Stimpson, M. L. et al. 2022. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. British Journal of Haematology 196(4), pp. 1113-1117. (10.1111/bjh.17884)
2021
- Dennis, M. et al. 2021. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances 5(24), pp. 5621-5625. (10.1182/bloodadvances.2021005038)
- Bradbury, C. A. et al. 2021. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England Journal of Medicine 385(10), pp. 885-895. (10.1056/NEJMoa2100596)
- Dennis, M. et al. 2021. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. British Journal of Haematology 194(2), pp. 298-308. (10.1111/bjh.17501)
- Burnett, A. K. et al. 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39(8), pp. 890-901. (10.1200/JCO.20.01170)
2020
- Greenwood, R., Pell, J., Foscarini-Craggs, P., Wale, K., Thomas, I. and Bradbury, C. 2020. Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK. Trials 21(1), article number: 873. (10.1186/s13063-020-04798-x)
2018
- Burnett, A. K. et al. 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32, pp. 2693-2714. (10.1038/s41375-018-0148-3)
- Freeman, S. D. et al. 2018. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. Journal of Clinical Oncology 36(14), pp. 1486-1497. (10.1200/JCO.2017.76.3425)
2017
- Knapper, S. et al. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9), pp. 1143-1154. (10.1182/blood-2016-07-730648)
2016
- Burnett, A. et al. 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101(6), pp. 724-731. (10.3324/haematol.2016.141937)
2015
- Burnett, A. K. et al. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25), pp. 3878-3885. (10.1182/blood-2015-01-623447)
- Khan, N. et al. 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170(1), pp. 80-84. (10.1111/bjh.13398)
- Dennis, M. et al. 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125(19), pp. 2923-2932. (10.1182/blood-2014-10-608117)
Articles
- Versluis, J. et al. 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42(34), pp. 4084-4094. (10.1200/JCO.23.02631)
- Russell, N. H. et al. 2024. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology (10.1200/JCO.24.00259)
- Voso, M. T. et al. 2024. Acute promyelocytic leukemia: Long-term outcomes from the HARMONY project. Blood (10.1182/blood.2024026186)
- Rodríguez-Arbolí, E. et al. 2024. Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML) [Letter to the Editor]. Leukemia 38(10) (10.1038/s41375-024-02378-5)
- Othman, J. et al. 2024. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood 144(7), pp. 714-728. (10.1182/blood.2024024310)
- Othman, J. et al. 2024. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143(19), pp. 1931-1936. (10.1182/blood.2023023096)
- Copland, M. et al. 2024. A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 204(3), pp. 871-876. (10.1111/bjh.19220)
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
- Mussai, F. et al. 2023. A randomised evaluation of low‐dose Ara‐ C plus pegylated recombinant arginase BCT ‐100 versus low dose Ara‐ C in older unfit patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 200(5), pp. 573-578. (10.1111/bjh.18560)
- Loo, S. et al. 2022. Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome [Letter]. Blood 140(22), pp. 2407-2411. (10.1182/blood.2022016567)
- Döhner, K. et al. 2022. Analysis of patient-level data from 3 cooperative group trials confirms a survival advantage for NPM1m patients achieving MRD-negative CR after intensive induction. Blood 140(S1), pp. 6293-6294. (10.1182/blood-2022-159212)
- Freeman, S. D. et al. 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140(S1), pp. 532-533. (10.1182/blood-2022-162245)
- Love, S. B. et al. 2022. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials 23, article number: 757. (10.1186/s13063-022-06680-4)
- Russell, N. H. et al. 2022. A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British Journal of Haematology 198(3), pp. 528-534. (10.1111/bjh.18195)
- Tazi, Y. et al. 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13(1), article number: 4622. (10.1038/s41467-022-32103-8)
- Russell, N. H. et al. 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107(7), pp. 1518-1527. (10.3324/haematol.2021.279010)
- Coats, T. et al. 2022. A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia. British Journal of Haematology 196(6), pp. 1337-1343. (10.1111/bjh.18013)
- Stimpson, M. L. et al. 2022. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. British Journal of Haematology 196(4), pp. 1113-1117. (10.1111/bjh.17884)
- Dennis, M. et al. 2021. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances 5(24), pp. 5621-5625. (10.1182/bloodadvances.2021005038)
- Bradbury, C. A. et al. 2021. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England Journal of Medicine 385(10), pp. 885-895. (10.1056/NEJMoa2100596)
- Dennis, M. et al. 2021. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. British Journal of Haematology 194(2), pp. 298-308. (10.1111/bjh.17501)
- Burnett, A. K. et al. 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39(8), pp. 890-901. (10.1200/JCO.20.01170)
- Greenwood, R., Pell, J., Foscarini-Craggs, P., Wale, K., Thomas, I. and Bradbury, C. 2020. Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK. Trials 21(1), article number: 873. (10.1186/s13063-020-04798-x)
- Burnett, A. K. et al. 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32, pp. 2693-2714. (10.1038/s41375-018-0148-3)
- Freeman, S. D. et al. 2018. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. Journal of Clinical Oncology 36(14), pp. 1486-1497. (10.1200/JCO.2017.76.3425)
- Knapper, S. et al. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9), pp. 1143-1154. (10.1182/blood-2016-07-730648)
- Burnett, A. et al. 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101(6), pp. 724-731. (10.3324/haematol.2016.141937)
- Burnett, A. K. et al. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25), pp. 3878-3885. (10.1182/blood-2015-01-623447)
- Khan, N. et al. 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170(1), pp. 80-84. (10.1111/bjh.13398)
- Dennis, M. et al. 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125(19), pp. 2923-2932. (10.1182/blood-2014-10-608117)